(c) 2014 Wiley Periodicals,

Inc. J. Appl. Polym. Sci. 2015, 132, 41265.”
“Farrar et al (1) demonstrate that modifying an oncolytic virus (OV) so that it produces excess protein when it infects a cancer cell is a process that can be detected both in vitro and in vivo in infected cancer cells by using chemical exchange saturation transfer (CEST) magnetic resonance (MR) imaging. The effect is at the limits of MR imaging detection (approximately 1%), but experience with functional MR imaging of the brain, with comparably small effects, should give pause to anyone who immediately writes this observation off as an exercise in wishful thinking. OVs are improving in their specificity, virulence, Stattic and ability to induce immune responses. Now, they have been modified to express proteins that are detectable with CEST Galardin solubility dmso MR imaging early after delivery into a tumor. This is clearly a surprising

and hopeful development in the long road of OVs from the laboratory to the clinic.”
“Dendrimeric platforms such as Multiple antigen peptides (MAPS) are regarded as one of the most efficacious approaches for antigenic presentation. Originally described as available by stepwise solid-phase peptide synthesis (SPPS), MAPS have also been prepared by chemical (thioether, oxime, hydrazone) ligation of appropriately functionalized tetra- or octavalent polylysine scaffolds with the peptide antigen to be multiply displayed. In this work, the advantages and limitations of two of the most frequent methods of MAP preparation,

namely, chemoselective thioether ligation in Solution, and all-solid-phase synthesis, Vorinostat in vivo have been tested in the case of a particularly troublesome epitope model, the ectodomain of protein M2 from influenza virus (M2e). The strong tendency of M2e to self-associate is a serious inconvenient for conjugation in solution, which as a result fails to produce the target MAPS with the specified number of M2e copies. In contrast, the fully stepwise SPPS approach is shown to be quite practical, especially when 6-aminohexanoic acid spacer units providing increased internal flexibility are inserted at each branching point.”
“BACKGROUND: Epidermal growth factor receptor (EGFR) promoter methylation may be responsible for the loss of EGFR expression in neoplastic cells. The primary aim of our study was to verify a possible correlation between EGFR gene promoter methylation and clinical outcome in metastatic colorectal cancer patients receiving chemotherapy with irinotecan and cetuximab.\n\nMETHODS: Colorectal samples from patients treated with irinotecan-cetuximab were analysed for EGFR promoter methylation and EGFR immunohistochemistry.\n\nRESULTS: Fifty-two patients were analysed. Thirty patients (58%) showed EGFR promoter hypermethylation.